Adeoye Y. Olukotun Sells 2,850 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Adeoye Y. Olukotun sold 2,850 shares of the firm’s stock in a transaction on Friday, December 27th. The stock was sold at an average price of $20.00, for a total value of $57,000.00. Following the sale, the director now directly owns 36,740 shares in the company, valued at $734,800. The trade was a 7.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Arrowhead Pharmaceuticals Stock Down 1.8 %

ARWR traded down $0.35 during trading on Monday, reaching $18.61. 1,126,742 shares of the stock were exchanged, compared to its average volume of 1,279,645. The stock has a market cap of $2.32 billion, a P/E ratio of -3.71 and a beta of 0.91. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74. The stock’s 50 day moving average price is $21.16 and its two-hundred day moving average price is $22.84. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $17.05 and a twelve month high of $39.83.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several hedge funds have recently bought and sold shares of ARWR. Franklin Resources Inc. boosted its stake in shares of Arrowhead Pharmaceuticals by 9.4% during the 3rd quarter. Franklin Resources Inc. now owns 19,251 shares of the biotechnology company’s stock worth $373,000 after acquiring an additional 1,658 shares during the period. World Investment Advisors LLC grew its position in shares of Arrowhead Pharmaceuticals by 3.8% in the third quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock valued at $371,000 after purchasing an additional 700 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Arrowhead Pharmaceuticals by 0.9% during the third quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock worth $57,426,000 after purchasing an additional 26,171 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at $345,000. Finally, Wellington Management Group LLP lifted its holdings in shares of Arrowhead Pharmaceuticals by 1.5% during the third quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company’s stock worth $1,199,000 after buying an additional 886 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ARWR shares. Sanford C. Bernstein dropped their price target on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research report on Friday, November 29th. Citigroup cut their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. Royal Bank of Canada reissued an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 26th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Friday, December 20th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $42.70.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.